Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test the safety, tolerability, and effectiveness of
two chemotherapy drugs, pegylated liposomal doxorubicin (Doxil) and bevacizumab (Avastin).
How Doxil is metabolized and excreted from the body will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
New Mexico Cancer Care Alliance
Collaborators:
Genentech, Inc. New York University School of Medicine NYU Langone Health